Weight Watchers has partnered with Eli Lilly's digital platform LillyDirect to offer its Med+ program, combining GLP-1 medication access with clinical and behavioral support. This integration aims to provide patients nationwide with a comprehensive weight management solution that goes beyond medication alone, addressing nutrition, behavior, and community support. The move responds to growing demand for GLP-1 treatments and enhances affordability and accessibility for users. Weight Watchers continues to lead in science-backed weight management by integrating medication with personalized care and support.
The 4-Factor Dividend Growth Strategy, inspired by the Schwab US Dividend Equity ETF (SCHD), targets high-quality dividend stocks using four specific metrics. Since its inception, it has delivered an average 12-month return of 16.94%, outperforming S...
Chai Discovery, an AI drug discovery startup, has secured major partnerships with pharmaceutical giants Pfizer and Eli Lilly to develop new antibody-based therapies using its advanced AI models. Valued at $1.3 billion, Chai recently launched its impr...
Biotech and pharma mergers and acquisitions (M&A) reached $106 billion across 201 deals in early 2026, driven by urgent needs to replace revenue from expiring drug patents and renewed investor interest. Despite rising interest rates and inflation, de...
Major investors are increasingly focusing on AI-driven biology and longevity, with startups like NewLimit tripling in value. While many of these startups remain private, NVIDIA and Eli Lilly stand out as the main public companies involved, partnering...
Eli Lilly reported a 55.5% revenue increase in Q1, driven by strong sales of Mounjaro and Zepbound totaling $12.8 billion. Despite this growth, shares have only risen slightly due to pricing pressures and charges from acquisitions and litigation. The...
